Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04576429

Immune Profiles Evolution Under Immunotherapy for Melanoma

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-04-06

360

Participants Needed

1

Research Sites

518 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective of the study aims to compare the immune profiles (circulating cytokines and lymphocytes) before and after (6 to 8 weeks) the first infusion of immune checkpoint inhibitors in patients with melanoma treated in the adjuvant setting(cohort A) or in metastatic setting(cohort B); and to study the association of these immune profiles with relapse- or progression-free survival.

CONDITIONS

Official Title

Immune Profiles Evolution Under Immunotherapy for Melanoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient aged 65 18 years
  • Totally resected stage III or IV melanoma treated with immune therapy (pembrolizumab, nivolumab, or other immune checkpoint inhibitors) as adjuvant treatment
  • Unresectable stage IIIC/D or IV metastatic melanoma treated with immune therapy (pembrolizumab, nivolumab, or other immune checkpoint inhibitors) combined with radiotherapy
  • Patient has been informed about the study and signed the consent
  • Affiliated to the French social security scheme
Not Eligible

You will not qualify if you...

  • Pregnant or breastfeeding woman
  • Patient refusal
  • Patient receiving an immunosuppressor
  • Undergoing general corticotherapy of > 10 mg/kg/day for more than 7 days
  • Patient participating in another blinded interventional study receiving blinded treatment
  • Patient without any social protection by organization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Dermato-oncology department, Ambroise Paré hospital, APHP

Boulogne-Billancourt, France, 92100

Actively Recruiting

Loading map...

Research Team

E

Elisa FUNCK-BRENTANO, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here